Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of LBL-034 in relapsed/refractory multiple myeloma
CTR20232974Phase 2Active
- Sponsor
- Leads Biolabs
- Start
- Nov 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LBL-034 in multiple myeloma (MM) and plasma cell leukaemia (PCL), sponsored by Leads Biolabs. Primary endpoints: Dose-limiting toxicity and maximum tolerated dose and Overall response rate. Started Nov 2023; status: active.
02
Drugs
LBL-034
03
Conditions
multiple myeloma (MM)plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on CTR20232974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232974.